4.6 Review

Review of Multi-Modal Imaging in Urea Cycle Disorders: The Old, the New, the Borrowed, and the Blue

Journal

FRONTIERS IN NEUROLOGY
Volume 12, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fneur.2021.632307

Keywords

urea cycle disorders; neuroimaging; hyperammonemia; magnetic resonance spectroscopy; ornithine transcarbamylase deficiency; arginase deficiency; multimodal imaging; functional near infrared spectroscopy

Funding

  1. Office of Rare Diseases Research (ORDR) [U54HD061221]
  2. National Center for Advancing Translational Science (NCATS) [U54HD061221]
  3. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [U54HD061221]
  4. O'Malley Foundation
  5. Kettering Fund

Ask authors/readers for more resources

The urea cycle disorders (UCD) are rare genetic disorders resulting from deficiencies in enzymes or proteins that remove waste nitrogen from the body. This review focuses on neuroimaging studies in two types of UCD, highlighting the cognitive and neurobehavioral impacts, especially on executive function and working memory. Clinical management aims at neuroprotection from hyperammonemia and other metabolites, with a major challenge and research focus on preventing neurological injury. Neuroimaging modalities, particularly multimodal imaging platforms, provide valuable information for understanding neurocognitive function and biomarkers, improving clinical decision-making and therapeutic interventions.
The urea cycle disorders (UCD) are rare genetic disorder due to a deficiency of one of six enzymes or two transport proteins that act to remove waste nitrogen in form of ammonia from the body. In this review, we focus on neuroimaging studies in OTCD and Arginase deficiency, two of the UCD we have extensively studied. Ornithine transcarbamylase deficiency (OTCD) is the most common of these, and X-linked. Hyperammonemia (HA) in OTCD is due to deficient protein handling. Cognitive impairments and neurobehavioral disorders have emerged as the major sequelae in Arginase deficiency and OTCD, especially in relation to executive function and working memory, impacting pre-frontal cortex (PFC). Clinical management focuses on neuroprotection from HA, as well as neurotoxicity from other known and yet unclassified metabolites. Prevention and mitigation of neurological injury is a major challenge and research focus. Given the impact of HA on neurocognitive function of UCD, neuroimaging modalities, especially multi-modality imaging platforms, can bring a wealth of information to understand the neurocognitive function and biomarkers. Such information can further improve clinical decision making, and result in better therapeutic interventions. In vivo investigations of the affected brain using multimodal neuroimaging combined with clinical and behavioral phenotyping hold promise. MR Spectroscopy has already proven as a tool to study biochemical aberrations such as elevated glutamine surrounding HA as well as to diagnose partial UCD. Functional Near Infrared Spectroscopy (fNIRS), which assesses local changes in cerebral hemodynamic levels of cortical regions, is emerging as a non-invasive technique and will serve as a surrogate to fMRI with better portability. Here we review two decades of our research using non-invasive imaging and how it has contributed to an understanding of the cognitive effects of this group of genetic conditions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available